IMNM today
$19.06-$0.01 (-0.05%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourBullish
1 hourExpanding
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns down below $16.41
Key levels
Resistance$20.84
Resistance$19.30
Support$17.29
Support$14.64
Latest news & SEC filings
AnalystImmunome Analysts Lower Forecasts Following Q3 Results
AnalystStifel keeps Hold rating on Immunome, cuts price target to $23
AnalystPiper Sandler keeps Overweight on Immunome, cuts price target to $30
All IMNM news →About Immunome
Immunome is a biotechnology company focused on creating cancer medicines, especially treatments that deliver a toxic payload to tumor cells via an antibody. Its most advanced candidate is an oral drug for desmoid tumors, a rare connective-tissue cancer, and it is also testing an experimental therapy for lymphomas and solid tumors plus a radioactive compound aimed at solid tumors. Earlier-stage programs target additional tumor types.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
Immunome Inc. (IMNM)
What Is the Price Target for IMNM?
SEPT Low Target
$24.00
SEPT Mid Target
$35.00
SEPT High Target
$38.00
Analyst Consensus
$35.00
Is IMNM a Buy or Sell Right Now?
Thesis
- •Revenue growing -23.2% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IMNM.
Start Free Trial →Is IMNM Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$29.10
27
Moat Score
NONE
4/9
Piotroski Score
17.7
Altman Z-Score
What Is Smart Money Doing with IMNM?
Insider Signal
NEUTRAL
6 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Horn Kinney | officer | Buy | 1,092 | $14K | Jul 7, 2026 |
| Horn Kinney | officer | Sale | 1,092 | $27K | Jul 7, 2026 |
| BIENAIME JEAN JACQUES | director | Sale | 500 | $10K | Jun 5, 2026 |
| BIENAIME JEAN JACQUES | director | Sale | 10,000 | $194K | Jun 5, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 6,000 | $117K | Jun 5, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 3,500 | $68K | Jun 5, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 1,000 | $19K | Jun 5, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 5,000 | $104K | May 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IMNM Growth Story
Revenue YoY
-23.2%
3yr Revenue CAGR
N/A%
EPS Growth YoY
51.4%
FCF Growth YoY
-70.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for IMNM
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IMNM, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:32:34 | $18.88 | 1,800 | $$34K | MIDPOINT |
| 21:00:17 | $19.07 | 4,300 | $$82K | BUY |
| 21:00:01 | $19.07 | 1,129 | $$22K | SELL |
| 20:57:58 | $19.11 | 2,000 | $$38K | MIDPOINT |
| 20:41:17 | $19.16 | 1,350 | $$26K | BUY |
5 dark pool trades shown · $$202K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Immunome Inc. (IMNM) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IMNM — frequently asked questions
What is IMNM stock price today?
Immunome Inc. (IMNM) is at $19.06, down 0.05% (-$0.01) at the Nov 12, 2026 close.
Why is IMNM stock moving today?
Latest IMNM news — Nov 10, 2026: Immunome Analysts Lower Forecasts Following Q3 Results · Nov 10, 2026: Stifel keeps Hold rating on Immunome, cuts price target to $23
Why did IMNM stock move on Oct 30, 2026?
Immunome announced that the European Medicines Agency validated and accepted its marketing authorization application for varegacestat, an oral drug being studied for adults with desmoid tumors. Validation means the filing is complete enough to be assessed by European regulators, a positive regulatory milestone for the company.
What is the IMNM price target?
The average analyst price target for IMNM is $35.00, ranging from $24 to $38, based on 6 analysts.
What do analysts rate IMNM?
Analyst ratings for IMNM: 16 Buy, 1 Hold, 0 Sell — consensus Strong Buy.
Did IMNM beat earnings?
IMNM last reported on Aug 11, 2026: EPS -$0.65 vs -$0.51 expected — a miss of 26.5%.
Does IMNM pay a dividend?
IMNM does not currently pay a dividend.
What are IMNM support and resistance levels?
Support: $17.29, $14.64, $11.25. Resistance: $19.30, $20.84, $22.77.
What are insiders doing with IMNM?
Insider activity: NEUTRAL, 6 buys and 8 sells in the last 90 days.
What is the latest news on IMNM?
Nov 10, 2026: Immunome Analysts Lower Forecasts Following Q3 Results · Nov 10, 2026: Stifel keeps Hold rating on Immunome, cuts price target to $23 · Nov 10, 2026: Piper Sandler keeps Overweight on Immunome, cuts price target to $30